{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Search results for sulfisoxazole root_names_name in Any Name (approximate match)
Status:
Possibly Marketed Outside US
Source:
NCT04677712: Phase 4 Interventional Completed Edematous Fibrosclerotic Panniculopathy (EFP)
(2020)
Source URL:
First approved in 2022
Source:
M020
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Possibly Marketed Outside US
Source:
21 CFR 348
(2022)
Source URL:
First approved in 2022
Source:
21 CFR 348
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Possibly Marketed Outside US
First approved in 2022
Source:
Dr. Zonskin Nunssup Jara by J 1010 Co., Ltd.
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Aceneuramic acid (also known as N-Acetylneuraminic Acid, Neu5Ac, the UX 001 tablets) prolonged released had been filed a marketing authorization application with the European Medicines Agency by Ultragenyx in the EU for the treatment of hereditary inclusion body myopathy (HIBM), a rare, progressive muscle-wasting disease. This compound, a muscle protein stimulant, is also in phase II of the clinical trial for the treatment thrombocytopenia. In addition, recently was made studies, which had shown, that existed the significant positive correlation between serum and salivary sialic acid levels in oral squamous cell carcinoma (OSCC) patients.
Status:
Possibly Marketed Outside US
Source:
21 CFR 352
(2021)
Source URL:
First approved in 2021
Source:
21 CFR 352
Source URL:
Class (Stereo):
CHEMICAL (EPIMERIC)
Status:
Possibly Marketed Outside US
Source:
M020
(2021)
Source URL:
First approved in 2021
Source:
M020
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Possibly Marketed Outside US
Source:
Mostal Lashes and Brows Enhancing Serum by Pella Pharmaceuticals Co. Ltd
(2020)
Source URL:
First approved in 2020
Source:
Mostal Lashes and Brows Enhancing Serum by Pella Pharmaceuticals Co. Ltd
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Possibly Marketed Outside US
Source:
21 CFR 333A
(2020)
Source URL:
First approved in 2020
Source:
21 CFR 333A
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Possibly Marketed Outside US
Source:
TBOSEN EMERGENCY STERILIZATION CARD by Jiangsu Tianbosheng Technology Co., Ltd.
(2020)
Source URL:
First approved in 2020
Source:
TBOSEN EMERGENCY STERILIZATION CARD by Jiangsu Tianbosheng Technology Co., Ltd.
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Possibly Marketed Outside US
Source:
M019
(2022)
Source URL:
First approved in 2020
Source:
505G(a)(3)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Possibly Marketed Outside US
Source:
505G(a)(3)
(2020)
Source URL:
First approved in 2020
Source:
505G(a)(3)
Source URL:
Class (Stereo):
CHEMICAL (RACEMIC)
